Phase 4
Completed N=38
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
Source: ClinicalTrials.gov NCT00455702 ↗Enrolled (actual)
38
Serious AEs
2.6%
Results posted
Aug 2014
Primary outcomePrimary: Main Outcome Measure: The Change From Baseline to Week 8 on the SANS — 2.06; -2.11 Units on a scale
Summary
The study aims to assess the effects of single dose and repeated weekly dosing of 50mg d-cycloserine versus placebo on cognitive and memory functioning in schizophrenia patients. The study will also examine the effects of 50mg d-cycloserine on positive symptoms and negative symptoms, as well as assess tolerability and side-effects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Main Outcome Measure: The Change From Baseline to Week 8 on the SANS |
2.06; -2.11 | — |
| SECONDARY Treatment Effects on the Positive Syndrome Subscale of the PANSS |
.19; -.19 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female
- Age 18-65 years
- Diagnosis of schizophrenia or schizoaffective disorder, depressed type
- Stable dose of antipsychotic for at least 4 weeks.
- Able to provide informed consent
- Able to complete a cognitive battery
Exclusion Criteria
- Current treatment with clozapine
- Dementia
- Seizure disorder
- Unstable medical illness
- Active substance abuse
- Pregnancy, nursing, or unwilling to use appropriate birth control measures during participation if female and fertile.
Data sourced from ClinicalTrials.gov (NCT00455702). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.